BioVie Inc.

Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for Alzheimer's disease. Their primary strategy involves targeting and inhibiting the production of toxic pyroglutamate-Abeta (pGlu-Abeta). The company's lead investigational compound, PQ912, is a small molecule QC inhibitor. This candidate has successfully completed Phase IIb clinical trials for both Alzheimer's disease and cancer. In its preclinical pipeline, Vivoryon is advancing PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor, specifically for cancer treatment. Additionally, the firm is developing a monoclonal antibody designed to enhance the clearance of pGlu-Abeta. Vivoryon Therapeutics maintains a robust network of collaborations, including a research agreement with University Medical Center Schleswig-Holstein focused on cancer immunotherapy, and a partnership with Nordic Bioscience for the clinical advancement of PQ912 in Alzheimer's disease. Further alliances include a research collaboration with the Fraunhofer Institute for cell therapy and immunology, and a strategic regional licensing agreement with Simcere Pharmaceutical Group Ltd. This latter partnership aims to develop and commercialize medicines specifically targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to address Alzheimer's disease. Established in 1997, Vivoryon Therapeutics N.V. is headquartered in Halle, Germany.

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.

Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily conducts research and innovation in living cell technologies within New Zealand. Its development portfolio includes AI-116, a novel combination treatment pairing donepezil with cannabidiol, designed to address various forms of dementia, such as Alzheimer's disease. Another key candidate is AI-168, a unique blend of a cannabinoid and an existing, off-patent drug component, aimed at managing cardiovascular conditions like hypertension. Additionally, Algorae is progressing with NTCELL, an alginate-encapsulated product for the treatment of Parkinson's disease. The company is also collaborating with the University of New South Wales to create AlgaraeOS, an advanced drug discovery platform that utilizes artificial intelligence protocols and extensive data analytics to optimize drug identification and development processes.

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.